Last reviewed · How we verify
Sisunatovir (sisunatovir)
Sisunatovir, developed by Pfizer Inc., was a drug in development but has since been discontinued. The specific mechanism involved participants receiving tablets from Day 1 to Day 5, though the primary indication and revenue details are not available. The primary risk is the discontinuation of the drug, which may impact Pfizer's portfolio and strategic investments in this therapeutic area.
At a glance
| Generic name | sisunatovir |
|---|---|
| Sponsor | Pfizer Inc. |
| Drug class | Participants will receive tablets from Day 1 to Day 5 |
| Therapeutic area | Infectious Disease |
| Phase | discontinued |
Approved indications
Pipeline indications
- Respiratory Syncytial Virus Infection — discontinued
Common side effects
Key clinical trials
- A Study to Learn About the Amount of the Study Medicine (Sisunatovir) in Blood and Its Safety in Infants and Children With Pneumonia Caused by RSV (PHASE1)
- A Study to Learn About the Study Medicine Sisunatovir in Adults With Respiratory Syncytial Virus (RSV) Infection (PHASE2, PHASE3)
- A Study to Learn About the Effects of Multiple Doses of Sisunatovir on People With Respiratory Syncytial Virus (RSV) Infection (PHASE2)
- A Study to Compare Different Preparations of Sisunatovir in Healthy Adult Participants. (PHASE1)
- A Study to Learn How a Medicine That Reduces Stomach Acid Affects the Level of Sisunatovir in the Blood of Healthy Adults. (PHASE1)
- A Study to Compare How the Study Medicine (PF-07923568) is Processed in Participants With Different Levels of Loss of Liver Function to Healthy Participants. (PHASE1)
- A Study to Learn How the Study Medicine Called Sisunatovir is Tolerated and Acts in the Bodies of Chinese Healthy Adults. (PHASE1)
- A Study to Investigate the Effects of Sisunatovir on QTc Interval in Healthy Adult Participants. (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Sisunatovir CI brief — competitive landscape report
- Sisunatovir updates RSS · CI watch RSS
- Pfizer Inc. portfolio CI